Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

204
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
204
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

371
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response...
371
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

527
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
527

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An activatable naphthalimide-based fluorescent probe for hydrogen peroxide detection: visualizing microcystin-LR induced oxidative stress in zebrafish and hepatocyte injury mechanism.

The Analyst·2026
Same author

Minimum noninferiority dose for phase I clinical trials with immunotherapy.

Biometrics·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.

Cancer letters·2026
Same author

VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy.

Molecular pharmaceutics·2026
Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026

Related Experiment Video

Updated: May 1, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.4K

BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.

Suyu Liu1, Guosheng Yin2, Ying Yuan1

  • 1MD Anderson Cancer Center.

The Annals of Applied Statistics
|April 8, 2014
PubMed
Summary
This summary is machine-generated.

Late-onset toxicities in adaptive dose-finding clinical trials are challenging. The new data augmentation continual re-assessment method (DA-CRM) effectively handles missing toxicity data, improving patient safety and maximum tolerated dose selection.

Keywords:
Bayesian adaptive designLate-onset toxicityNonignorable missing dataPhase I clinical trial

More Related Videos

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay
06:25

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay

Published on: January 12, 2024

2.2K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

666

Related Experiment Videos

Last Updated: May 1, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.4K
Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay
06:25

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay

Published on: January 12, 2024

2.2K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

666

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Adaptive dose-finding designs are crucial for early-phase clinical trials.
  • A significant challenge is the delayed observation of toxicity outcomes, impacting decision-making.
  • Existing methods struggle with late-onset toxicities in dose escalation.

Purpose of the Study:

  • To introduce a novel method, the data augmentation continual re-assessment method (DA-CRM), to address late-onset toxicities in dose-finding studies.
  • To develop a robust statistical framework for handling non-ignorable missing toxicity data.
  • To improve the safety and efficiency of dose-finding trials.

Main Methods:

  • The DA-CRM treats unobserved toxicities as missing data, acknowledging their dependence on unobserved outcomes.
  • A Bayesian data augmentation approach is employed to sample missing data and model parameters.
  • The method's performance is evaluated through extensive simulations and comparisons with existing techniques.

Main Results:

  • The DA-CRM effectively resolves issues associated with late-onset toxicities.
  • Simulations demonstrate desirable operating characteristics, including enhanced patient safety.
  • The proposed design shows a higher probability of correctly identifying the maximum tolerated dose.

Conclusions:

  • The DA-CRM offers a statistically sound and practical solution for dose-finding when toxicities are delayed.
  • This method enhances patient safety and optimizes the selection of the maximum tolerated dose in phase I cancer trials.
  • The DA-CRM represents a significant advancement in adaptive clinical trial design for oncology research.